Analysts on Wall Street project that TransMedics (TMDX) will announce quarterly earnings of $0.28 per share in its forthcoming report, representing an increase of 333.3% year over year. Revenues are projected to reach $114.22 million, increasing 71.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a co ...

TransMedics Group (TMDX) is scheduled to report third-quarter 2024 results on Oct. 28, after market close.In the last reported quarter, the company’s adjusted earnings per share of 35 cents surpassed the Zacks Consensus Estimate by 66.7%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 287.5%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.TMDX’s Q3 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $114.2 million, imp ...

Wall Street expects a year-over-year increase in earnings on higher revenues when TransMedics (TMDX) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 2 ...

I first became aware of TransMedics Group, Inc. (NASDAQ: TMDX ) through social media earlier this year and purchased my first shares in April of this year. While this was a very small My primary area of concentration will be on identifying companies of exceptional caliber, with a proven ability to reinvest capital for impressive returns. Targeting those with a market capitalization of less than $10 billion, affords ample opportunities for growth. The ideal scenario is for these companies to demonstrate a lo ...

ANDOVER, Mass., Oct. 15, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with endstage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2024 after market close on Monday, October 28, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listeni ...

Overview of FMR LLC (Trades, Portfolio)'s Recent Transaction On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ transplant technology. This move reduced FMR LLC (Trades, Portfolio)'s holdings in the company by 50.82%, leaving them with a total of 2,208,308 shares. The shares were traded at a price of $157 each, reflecting a strategie adjustment in FMR LLC (Trades, ...

TransMedics (TMDX) closed the last trading session at $143.80, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $181.89 indicates a 26.5% upside potential. The average comprises nine short-term price targets ranging from a low of $153 to a high of $208, with a standard deviation of $17.60. While the lowest estimate indicates an increase of 6.4% from the current price le ...

TransMedics (TMDX) shares rallied 10.1% in the last trading session to close at $159.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 13.3% loss over the past four weeks. TransMedics scored a strong price increase driven by investors' optimism following the news of the company joining the S&P SmallCap 600. On Sept. 26, per S&P Dow Jones' press release, Transmedics will replace The Ensign Group in the S&P S ...

sturti Investment Thesis TransMedics (NASDAQ:TMDX) is a company that is revolutionizing the way organs are transported for transplants. This is a statement that puts a lot of weight on the company, but so far, it has proven to be true and sales continue to grow +100% YoY with net margins of 10 to 12%. Despite strong competitive advantages, TMDX is trading at less than 11 times EV/Sales, while recently acquired companies and some competitors are trading at more than 17 times, making it a buying opportunity. ...

TransMedics' revolutionary Organ Care System, high sales growth, and newfound profitability combine with its towering valuation to create wild volatility. Shares of TransMedics (TMDX -5.03%), a leader in heart, lung, and liver transplant technologies, have plummeted 15% in the past week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. While no specific news led to the company's drop, the movement is probably tied to the stock's increasing volatility following a remarka ...